Recently, other distinct molecular subgroups of treatment-resistant tumors have been described which are either composed of tumor cells coexpressing both AR and neuroendocrine markers (amphicrine prostate cancer) or those that are double-negative for both (3, 20). This evidence concerns the gene AR and neoplasm.